Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, has issued a stockholder letter highlighting its progress in oncology and diabetes programs. Under the leadership of CEO Ryan Confer, the company reports significant advancements in its clinical development initiatives, particularly in two ongoing lung cancer trials.
The company emphasizes its commitment to developing novel gene therapies for cancer and diabetes patients, with multiple milestones expected in the second half of 2025. Genprex maintains its focus on streamlined strategies to build company-wide value while advancing its clinical programs.
Genprex (NASDAQ: GNPX), un'azienda di terapia genica in fase clinica, ha pubblicato una lettera agli azionisti evidenziando i progressi nei suoi programmi per oncologia e diabete. Sotto la guida del CEO Ryan Confer, la società riferisce notevoli avanzamenti nelle iniziative di sviluppo clinico, in particolare in due studi clinici in corso sul cancro ai polmoni.
L'azienda sottolinea il suo impegno nello sviluppo di nuove terapie geniche per pazienti affetti da cancro e diabete, con diversi traguardi previsti nella seconda metà del 2025. Genprex mantiene il focus su strategie semplificate per creare valore a livello aziendale, proseguendo nello sviluppo dei suoi programmi clinici.
Genprex (NASDAQ: GNPX), una compañía de terapia génica en fase clínica, ha emitido una carta a los accionistas destacando su progreso en los programas de oncología y diabetes. Bajo el liderazgo del CEO Ryan Confer, la empresa informa avances significativos en sus iniciativas de desarrollo clínico, especialmente en dos ensayos en curso para cáncer de pulmón.
La compañía enfatiza su compromiso con el desarrollo de nuevas terapias génicas para pacientes con cáncer y diabetes, con múltiples hitos esperados en la segunda mitad de 2025. Genprex mantiene su enfoque en estrategias simplificadas para generar valor en toda la empresa mientras avanza en sus programas clínicos.
Genprex (NASDAQ: GNPX)는 임상 단계의 유전자 치료 회사로서, 종양학 및 당뇨병 프로그램에서의 진전을 강조하는 주주 서한을 발행했습니다. CEO 라이언 콘퍼(Ryan Confer)의 리더십 아래 회사는 특히 진행 중인 두 건의 폐암 임상 시험에서 임상 개발 이니셔티브에 상당한 진전을 보고했습니다.
회사는 암과 당뇨병 환자를 위한 혁신적인 유전자 치료제 개발에 전념하고 있으며, 2025년 하반기에 여러 중요한 이정표를 달성할 것으로 기대하고 있습니다. Genprex는 임상 프로그램을 진전시키면서 회사 전반의 가치를 창출하기 위한 간소화된 전략에 집중하고 있습니다.
Genprex (NASDAQ : GNPX), une entreprise de thérapie génique en phase clinique, a publié une lettre aux actionnaires mettant en avant ses progrès dans les programmes d'oncologie et de diabète. Sous la direction du PDG Ryan Confer, la société rapporte des avancées significatives dans ses initiatives de développement clinique, notamment dans deux essais en cours sur le cancer du poumon.
L'entreprise souligne son engagement à développer de nouvelles thérapies géniques pour les patients atteints de cancer et de diabète, avec plusieurs étapes clés attendues dans la seconde moitié de 2025. Genprex maintient son focus sur des stratégies simplifiées pour créer de la valeur à l'échelle de l'entreprise tout en faisant progresser ses programmes cliniques.
Genprex (NASDAQ: GNPX), ein Unternehmen für Gentherapie in der klinischen Phase, hat einen Aktionärsbrief veröffentlicht, in dem die Fortschritte in den Onkologie- und Diabetesprogrammen hervorgehoben werden. Unter der Leitung von CEO Ryan Confer berichtet das Unternehmen von bedeutenden Fortschritten in seinen klinischen Entwicklungsinitiativen, insbesondere bei zwei laufenden Lungenkrebsstudien.
Das Unternehmen betont sein Engagement für die Entwicklung neuartiger Gentherapien für Krebspatienten und Diabetespatienten, mit mehreren Meilensteinen, die in der zweiten Hälfte des Jahres 2025 erwartet werden. Genprex konzentriert sich weiterhin auf schlanke Strategien, um unternehmensweiten Wert zu schaffen und gleichzeitig seine klinischen Programme voranzutreiben.
- Continued progress in multiple clinical development programs
- Active advancement of two lung cancer clinical trials
- Strategic focus on both oncology and diabetes markets
- Limited specific details about clinical trial progress or results
- No concrete financial metrics or funding updates provided
Company Achieves Multiple Clinical Development Milestones in 2025
Patient Treatment Continues in Two Lung Cancer Clinical Trials
"Genprex has made significant progress across our technology programs this past year, and I am enthusiastic about Genprex's future as we continue to advance our clinical development program while maintaining streamlined, focused strategies that are important to build value across the entire company," said Ryan Confer, President and Chief Executive Officer. "We remain dedicated to transforming lives of patients battling cancer and diabetes through our novel gene therapies, and we look forward to executing on a number of upcoming milestones in the second half of 2025 and beyond."
To read the stockholder letter in its entirety, a digital copy of the Company's stockholder letter can be found on the Company's website here.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-issues-stockholder-letter-and-provides-2025-corporate-update-302519361.html
SOURCE Genprex, Inc.
FAQ
What major developments did Genprex (GNPX) announce in its 2025 corporate update?
What clinical trials is Genprex (GNPX) currently conducting?
Who is the current CEO of Genprex (GNPX)?
What therapeutic areas does Genprex (GNPX) focus on?
Where can investors find Genprex's 2025 stockholder letter?
